Abstract
Dyskalaemia is associated with poor prognosis in heart failure (HF). Hyperkalaemia often leads to interruption and discontinuation of neurohormonal antagonists, potentially aggravating prognosis. Sodium-glucose co-transporter 2 inhibitors improve HF prognosis across a wide range of ejection fraction and may reduce hyperkalaemia, which may have important clinical implications. We studied prognostic associations of dyskalaemia and the effect of empagliflozin on the occurrence of hyper- and hypokalaemia in HF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
